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Background: Diabetes and chronic kidney disease (CKD) are independent predictors of death and cardiovascular
events and their concomitant prevalence has increased in recent years. The aim of this study was to characterize the
effect of the estimated glomerular filtration rate (eGFR) and other factors on the risk of death and cardiovascular events
in patients with type 2 diabetes.
Methods: A cohort of 57,946 patients with type 2 diabetes who were aged 20–89 years in 2000–2005 was identified
from The Health Improvement Network, a UK primary care database. Incidence rates of death, myocardial infarction
(MI), and ischemic stroke or transient ischemic attack (IS/TIA) were calculated overall and by eGFR category at baseline.
eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) study equation. Death, MI and IS/TIA cases
were detected using an automatic computer search and IS/TIA cases were further ascertained by manual review of
medical records. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for death, MI, and IS/TIA
associated with eGFR category and other factors were estimated using Cox regression models adjusted for potential
confounders.
Results: Overall incidence rates of death (mean follow-up time of 6.76 years), MI (6.64 years) and IS/TIA (6.56 years)
were 43.65, 9.26 and 10.39 cases per 1000 person-years, respectively. A low eGFR (15–29 mL/min) was associated with
an increased risk of death (HR: 2.79; 95% CI: 2.57–3.03), MI (HR: 2.33; 95% CI: 1.89–2.87) and IS/TIA (HR: 1.77; 95% CI:
1.43–2.18) relative to eGFR ≥ 60 mL/min. Other predictors of death, MI and IS/TIA included age, longer duration of
diabetes, poor control of diabetes, hyperlipidemia, smoking and a history of cardiovascular events.
Conclusions: In patients with type 2 diabetes, management of cardiovascular risk factors and careful monitoring of
eGFR may represent opportunities to reduce the risks of death, MI and IS/TIA.
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Type 2 diabetesBackground
Diabetes and chronic kidney disease (CKD) are independ-
ent predictors of death and cardiovascular events [1-3].
The prevalence of CKD in individuals with diabetes has
increased in recent years and studies have estimated that
about 25–30% of patients with type 2 diabetes have CKD* Correspondence: lagarcia@ceife.es
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unless otherwise stated.stages 3–5 in the UK [4,5]. Additionally, type 2 diabetes is
the most common reason for renal replacement therapy
in the Western world [6].
The potential association between impaired renal func-
tion (as measured by the estimated glomerular filtration
rate [eGFR]) and all-cause mortality and/or incidence of
cardiovascular events has been thoroughly studied in the
general population [1,7-11], in patients with cardiovascu-
lar diseases [12-16] and in those with impaired renal func-
tion [17,18]. Although the association between decreasedntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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betes has been studied to some extent [19-24], data on
cardiovascular mortality and morbidity remain scarce in
this patient population [19,20,24-28].
The aim of this study was to determine the inci-
dences of death, myocardial infarction (MI), and ische-
mic stroke or transient ischemic attack (IS/TIA) in a
population of individuals with prevalent type 2 dia-
betes, overall and according to eGFR calculated from
baseline measurement of creatinine. Risks of death, MI
and IS/TIA adjusted for potential confounders (includ-
ing cardiovascular risk factors) and associated with
eGFR baseline measurement was also estimated. Other
predictors of death and cardiovascular outcomes were
also identified overall and for each CKD stage.
Methods
Data source
A retrospective cohort study was performed using data
from The Health Improvement Network (THIN), a
computerized primary care database containing anon-
ymized records for individuals currently registered
with participating primary care practices in the UK.
THIN is age, sex and geographically representative of
the UK population [29] and has been extensively vali-
dated for epidemiological studies [30,31]. Anonymized
data on patients are systematically recorded by partici-
pating primary care physicians (PCPs) as part of their
routine patient care and regularly delivered to THIN
for use in research projects. The computerized infor-
mation includes demographics, details of PCP visits,
diagnoses, referrals to specialists and hospital admis-
sions, and a free-text section. Participating practices
are required to record prescriptions and new courses
of therapy. THIN also provides a standardized system
for the reliable and comprehensive recording of add-
itional health data such as results of laboratory tests
(including serum creatinine concentration, when ap-
propriate). The Read classification is used to code spe-
cific diagnoses [32], and a drug dictionary based on
data from the Multilex classification is used to record
prescriptions [33]. The collection of data in THIN
database was approved by a Multicentre Research Eth-
ics Committee in the UK (MREC reference number:
08/H0305/49).
Study design
A cohort of patients with diagnosed type 2 diabetes
who were aged 20–89 years between January 1, 2000
and December 31, 2005 was identified from THIN
(n = 64,755). The wide age range was chosen to in-
clude the general adult population with prevalent
type 2 diabetes. Eligible individuals were required to
be registered for at least 3 years with their PCP, tohave had at least one visit recorded in the past 3 years,
and to have a recorded prescription history of 3 years
or more. Patients were included in the study cohort if
they had at least one creatinine measurement of 10–
250 μmol/L recorded between 1 January 2000 and 31
December 2005. Patients with a record of hemodialysis
(n = 109) or renal transplant (n = 60) before their start
date were excluded, and patients with a recorded inci-
dence of hemodialysis or renal transplant during
follow-up were censored from the analysis (n = 108 for
hemodialysis and n = 5 for renal transplant).
Among all individuals with type 2 diabetes meet-
ing these criteria (n = 57,957), 56,693 (97.8%) had a
first recorded creatinine measurement of 10–
250 μmol/L. The date of this first recorded creatin-
ine measurement was defined as their start date.
The remaining 1264 individuals (2.2%) had a first
creatinine measurement < 10 μmol/L (n = 1161) or >
250 μmol/L (n = 103), and a subsequent measure-
ment within the range 10–250 μmol/L. The date of
their first serum creatinine measurement between 10
and 250 μmol/L was defined as their start date. The
mean and median times from their first recorded
measurement to their start date were 341 days and
202 days, respectively. All patients were followed up
from their start date to the first occurrence of either
of the following endpoints in three different analyses
based on the studied outcome: outcome of interest
(death, MI or IS/TIA), reaching the age of 90 years,
or end of the study period (December 31, 2010). It
should be noted that 11 patients were excluded from
the final cohort (seven individuals who had died at
start date, and four who had no visits during follow-
up), resulting in a final cohort of 57,946 patients.
Ascertainment and duration of type 2 diabetes
Type 2 diabetes diagnosis was based on the Read clas-
sification codes assigned by the PCP or use of
hypoglycemic drugs or insulin. For the majority of
cases, the type of diabetes was specifically reported by
the physician. If the physician used an unspecific diag-
nostic code (e.g., diabetes mellitus), we reviewed the
patient’s medical record back to one year before the
diagnosis including any referral letters and physicians’
free-text comments to assign the type of diabetes. If
the age of onset was ≤ 35 years and the patient had one
or more prescriptions for insulin and less than one
year of oral hypoglycemic treatment, the case was clas-
sified as type 1 diabetes. Conversely, if the age of onset
was ≥ 50 years and the patient used oral hypoglycemic
treatment for at least 1 year, the case was classified as
type 2 diabetes. A previous THIN study with a similar
diabetes ascertainment algorithm estimated a diabetes
prevalence that closely matched the prevalence in the
Table 1 Baseline characteristics, overall and according to estimated glomerular filtration rate category
eGFR category (mL/min)
Overall (N = 57,946) 15–29 (n = 972) 30–44 (n = 4326) 45–59 (n = 12,614) ≥ 60 (n = 40,034)
Number % Number % Number % Number % Number %
Sex
Men 32,117 55.4 315 32.4 1654 38.2 5434 43.1 24,714 61.7
Women 25,829 44.6 657 67.6 2672 61.8 7180 56.9 15,320 38.3
Age at start date (years)
20–39 1269 2.2 0 0.0 3 0.1 30 0.2 1236 3.1
40–49 4454 7.7 8 0.8 27 0.6 187 1.5 4232 10.6
50–59 10,729 18.5 37 3.8 175 4.0 1067 8.5 9450 23.6
60–69 17,889 30.9 196 20.2 883 20.4 3623 28.7 13,187 32.9
70–79 16,933 29.2 378 38.9 1882 43.5 5303 42.0 9370 23.4
80–89 6672 11.5 353 36.3 1356 31.3 2404 19.1 2559 6.4
Smoking status
Non-smoker 30,175 52.1 561 57.7 2441 56.4 7028 55.7 20,145 50.3
Current 10,128 17.5 104 10.7 533 12.3 1671 13.2 7820 19.5
Former 15,011 25.9 240 24.7 1105 25.5 3367 26.7 10,299 25.7
Unknown 2632 4.5 67 6.9 247 5.7 548 4.3 1770 4.4
BMI (kg/m2)
15–19 915 1.6 18 1.9 84 1.9 234 1.9 579 1.4
20–24 9546 16.5 174 17.9 818 18.9 2223 17.6 6331 15.8
25–29 21,011 36.3 297 30.6 1521 35.2 4757 37.7 14,436 36.1
≥ 30 22,959 39.6 362 37.2 1487 34.4 4529 35.9 16,581 41.4
Unknown 3515 6.1 121 12.4 416 9.6 871 6.9 2,107 5.3
Number of drugs
≤1 15,007 25.9 107 11.0 626 14.5 2708 21.5 11,566 28.9
2–4 20,458 35.3 224 23.0 1185 27.4 4121 32.7 14,928 37.3
5–9 18,680 32.2 461 47.4 1920 44.4 4748 37.6 11,551 28.9
10–14 3335 5.8 158 16.3 513 11.9 906 7.2 1758 4.4
≥15 466 0.8 22 2.3 82 1.9 131 1.0 231 0.6
Duration of diabetes (years)
<1 2848 4.9 26 2.7 138 3.2 557 4.4 2127 5.3
1–4 23,201 40.0 208 21.4 1311 30.3 4545 36.0 17,137 42.8
5–9 17,123 29.5 298 30.7 1271 29.4 3786 30.0 11,768 29.4
10–14 8503 14.7 184 18.9 824 19.0 2095 16.6 5400 13.5
≥15 6271 10.8 256 26.3 782 18.1 1631 12.9 3602 9.0
HbA1c (%)
<7.00 19,382 33.4 272 28.0 1463 33.8 4480 35.5 13,167 32.9
7.00–7.99 12,823 22.1 203 20.9 964 22.3 2922 23.2 8734 21.8
8.00–8.99 7221 12.5 111 11.4 480 11.1 1565 12.4 5065 12.7
9.00–9.99 4634 8.0 66 6.8 302 7.0 877 7.0 3389 8.5
10.00–10.99 2497 4.3 44 4.5 142 3.3 433 3.4 1878 4.7
≥11 2301 4.0 43 4.4 134 3.1 409 3.2 1715 4.3
Missing 9088 15.7 233 24.0 841 19.4 1928 15.3 6086 15.2
PCP visits
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Table 1 Baseline characteristics, overall and according to estimated glomerular filtration rate category (Continued)
0–4 8018 13.8 87 9.0 471 10.9 1508 12.0 5952 14.9
5–9 17,371 30.0 229 23.6 1120 25.9 3640 28.9 12,382 30.9
10–19 23,024 39.7 355 36.5 1717 39.7 5228 41.4 15,724 39.3
≥20 9533 16.5 301 31.0 1018 23.5 2238 17.7 5976 14.9
Referrals
0–4 50,987 88.0 750 77.2 3634 84.0 10,976 87.0 35,627 89.0
5–9 5525 9.5 162 16.7 513 11.9 1287 10.2 3563 8.9
10–19 1315 2.3 55 5.7 162 3.7 325 2.6 773 1.9
≥20 119 0.2 5 0.5 17 0.4 26 0.2 71 0.2
Hospitalizations
None 52,092 89.9 735 75.6 3676 85.0 11,206 88.8 36,475 91.1
1–2 5013 8.7 176 18.1 524 12.1 1190 9.4 3123 7.8
≥3 841 1.5 61 6.3 126 2.9 218 1.7 436 1.1
Townsend deprivation index
1 (least deprived) 11,719 20.2 146 15.0 752 17.4 2445 19.4 8376 20.9
2 11,797 20.4 173 17.8 811 18.7 2515 19.9 8298 20.7
3 11,672 20.1 214 22.0 884 20.4 2586 20.5 7988 20.0
4 11,548 19.9 223 22.9 958 22.1 2486 19.7 7881 19.7
5 (most deprived) 8203 14.2 155 15.9 682 15.8 1875 14.9 5491 13.7
Unknown 3007 5.2 61 6.3 239 5.5 707 5.6 2000 5.0
Practice location
Urban 38,467 66.4 628 64.6 2862 66.2 8,443 66.9 26,534 66.3
Town 6335 10.9 114 11.7 476 11.0 1,207 9.6 4,538 11.3
Rural 3373 5.8 55 5.7 239 5.5 703 5.6 2,376 5.9
Unknown 9771 16.9 175 18.0 749 17.3 2,261 17.9 6,586 16.5
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PCP, primary care physician.
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tion survey [34,35].
Duration of diabetes was defined as the time interval
between the first ever recorded entry for type 2 dia-
betes in the database (including treatment for diabetes)
and the start date (date of the first ever valid recorded
serum creatinine measurement). Duration of diabetes
was categorized into five groups: < 1 year, 1–4 years,
5–9 years, 10–14 years and ≥ 15 years.
Estimated glomerular filtration rate
The modification of diet in renal disease (MDRD)
study formula and the Cockcroft–Gault formula are
routinely used to calculate eGFR from serum creatin-
ine concentration. In this study, the eGFR at baseline
was calculated using the MDRD study formula
(eGFR = 186 × Cr–1.154 × age–0.203 × 1.212 [if black] ×
0.742 [if female], where Cr is the serum creatinine
concentration in mg/dL). Ethnicity is not recorded in
THIN, hence the same formula was used for all pa-
tients (eGFR = 186 × Cr–1.154 × age–0.203 × 0.742 [if fe-
male]) to classify them into five subgroups accordingto their baseline eGFR: < 15 mL/min (CDK stage 5),
15–29 mL/min (CKD stage 4), 30–44 mL/min (CKD
stage 3B), 45–59 mL/min (CKD stage 3A) and ≥
60 mL/min (CKD stages 1 and 2, or no CKD).
Myocardial infarction ascertainment
An automatic computer search for specific Read codes
was used for the ascertainment of MI cases. Previous
studies using this method have shown a very high spe-
cificity for MI, resulting in a confirmation rate greater
than 90% when validated with the PCP via a question-
naire [36]. Therefore, additional steps of validation of
the ascertainment of MI cases, such as manual review
of patients’ profiles or validation with a questionnaire,
were not carried out in the present study. A total of
3435 cases of MI were identified.
Ischemic stroke ascertainment
The predictive value of computer-detected IS/TIA is
lower than that for other outcomes such as MI owing
to the level of misclassification of diagnoses using Read
codes. Therefore, we used a multistep approach to
Table 2 Comorbidities recorded any time before the start date, overall and according to eGFR category
eGFR category (mL/min)
Overall (N = 57,946) 15–29 (n = 972) 30–44 (n = 4326) 45–59 (n = 12,614) ≥60 (n = 40,034)
Number % Number % Number % Number % Number %
MI 5581 9.6 196 20.2 729 16.9 1499 11.9 3157 7.9
IS/TIA 5675 9.8 207 21.3 774 17.9 1677 13.3 3017 7.5
COPD 2651 4.6 85 8.7 279 6.4 725 5.7 1562 3.9
Thyroid disease 4932 8.5 145 14.9 595 13.8 1441 11.4 2751 6.9
Hypertension 32,752 56.5 664 68.3 2931 67.8 8197 65.0 20,960 52.4
Renal hypertension 29 0.1 4 0.4 7 0.2 6 0.0 12 0.0
Hyperlipidemia 3998 6.9 323 33.2 891 20.6 1342 10.6 1442 3.6
DVT 3429 5.9 106 10.9 373 8.6 933 7.4 2017 5.0
PAD 3695 6.4 158 16.3 554 12.8 1026 8.1 1957 4.9
Anemia 3561 6.1 178 18.3 539 12.5 949 7.5 1895 4.7
Atrial fibrillation 3494 6.0 67 6.9 265 6.1 742 5.9 2420 6.0
Heart failure 4011 6.9 73 7.5 313 7.2 853 6.8 2772 6.9
Peptic ulcer disease 3676 6.3 89 9.2 354 8.2 880 7.0 2353 5.9
Chronic liver disease 685 1.2 10 1.0 47 1.1 134 1.1 494 1.2
Gout 3599 6.2 134 13.8 480 11.1 876 6.9 2109 5.3
Osteoporosis 1253 2.2 37 3.8 148 3.4 386 3.1 682 1.7
Cancer 5295 9.1 119 12.2 620 14.3 1434 11.4 3122 7.8
Anxiety 6171 10.6 122 12.6 453 10.5 1354 10.7 4242 10.6
GERD 6152 10.6 121 12.4 546 12.6 1493 11.8 3992 10.0
COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; GERD, gastroesophageal reflux disease; IS,
ischemic stroke; MI, myocardial infarction; PAD, peripheral arterial disease; TIA, transient ischemic attack.
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tailed description). Briefly, a computer search using
Read codes suggestive of IS/TIA identified 4799 poten-
tial cases. Among these cases, 902 were matched to pa-



























Figure 1 Incidence rates of death, myocardial infarction (MI) and ischemic
both overall and according to estimated glomerular filtration rate (eGFR) caa diagnosis of IS/TIA in THIN [37,38]; 653 were classi-
fied as non-cases and 249 as cases. For the remaining
3897 patients, the cases of IS/TIA were ascertained in
a stepwise fashion by first searching for indicators of
hospitalization or referral and then searching for44 mL/min
R category
45–59 mL/min ≥ 60 mL/min





stroke (IS)/transient ischemic attack (TIA). Incidence rates are shown
tegory. Black vertical lines represent 95% confidence intervals.
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Figure 2 Kaplan–Meier survival estimates. Cumulative incidence of
(A) death, (B) myocardial infarction and (C) ischemic stroke or
transient ischemic attack according to estimated glomerular filtration
rate (eGFR) category.
Table 3 HRs of death, MI and IS/TIA associated with eGFR
category
Death MI IS/TIA
HRa (95% CI) HRa (95% CI) HRa (95% CI)
eGFR calculated with the MDRD study equation, mL/min
15–29 2.79 (2.57–3.03) 2.34 (1.90–2.88) 1.78 (1.44–2.19)
30–59 1.38 (1.33-1.43) 1.37 (1.27-1.48) 1.13 (1.05-1.22)
30–44 1.83 (1.74–1.92) 1.75 (1.56–1.97) 1.27 (1.13–1.43)
45–59 1.25 (1.20–1.30) 1.27 (1.17–1.38) 1.09 (1.01–1.18)
≥60 1 (−) 1 (−) 1 (−)
eGFR calculated with the CKD-EPI equation, mL/min
15–29 2.79 (2.59–2.99) 2.21 (1.83–2.66) 1.73 (1.44–2.09)
30–59 1.41 (1.36-1.46) 1.38 (1.28-1.49) 1.20 (1.12-1.29)
30–44 1.75 (1.67–1.84) 1.72 (1.54–1.92) 1.28 (1.15–1.43)
45–59 1.29 (1.24–1.34) 1.27 (1.17–1.38) 1.19 (1.09–1.27)
≥60 1 (−) 1 (−) 1 (−)
aAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status,
number of medications, HbA1c level, presence of hypertension hyperlidemia,
and history of MI, IS/TIA and IHD.
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; HbA1c, glycated hemoglobin; HR, hazard ratio; IHD, ischemic
heart disease; IS, ischemic stroke; MI, myocardial infarction; TIA, transient
ischemic attack.
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new treatment related to stroke in the 30 days before
and after the date of the computer-detected IS/TIA. Fi-
nally, the profiles (including free text) of sample pa-
tients from different subgroups were manually
reviewed to validate the ascertainment of cases. Over-
all, we identified 3785 cases of IS/TIA.
Data collection
Data on demographic variables including sex, age,
smoking status, alcohol use, body mass index (BMI) and
Townsend deprivation index (a measure of material
deprivation within a population that takes into account
four main variables: unemployment rate, car ownership,
home ownership and household overcrowding) [39]
were collected any time before the start date. Exposure
to drugs was collected before the start date and catego-
rized as follows: current use, when the supply of the
most recent prescription lasted until the start date or
ended in the 90 days before the start date; recent use,
when supply of the most recent prescription ended
more than 90 days before the start date; and non-use,
when there was no recorded use any time before the
start date. Data on healthcare service use (PCP visits, re-
ferrals and hospitalizations) were collected for the year
before the start date. Information on comorbidities was
collected any time before the start date. Data on levels
of glycated hemoglobin (HbA1c) were collected for the
year before the start date. Patients were classified into
Table 4 HRs of death associated with potential risk factors, overall and stratified by eGFR category
Non-death Death eGFR category
n = 41,368 n = 16,578 Overall 15–29 mL/min 30–44 mL/min 45–59 mL/min ≥60 mL/min
Number (%) Number (%) HRa (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI)
Sex
Men 22,752 (55.0) 9365 (56.5) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Women 18,616 (45.0) 7213 (43.5) 0.80 (0.77–0.82) 1.03 (0.87–1.21) 0.77 (0.71–0.84) 0.79 (0.75–0.84) 0.78 (0.74–0.82)
Age at start date (years)
20–49 5428 (13.1) 295 (1.8) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
50–74 29,403 (71.1) 8669 (52.3) 3.90 (3.47–4.39) 0.60 (0.25–1.48) 2.62 (1.24–5.54) 2.43 (1.62–3.63) 3.75 (3.30–4.25)
≥75 6537 (15.8) 7614 (45.9) 11.24 (9.97–12.67) 0.97 (0.40–2.40) 5.12 (2.43–10.80) 6.40 (4.27–9.58) 13.01 (11.42–14.83)
Duration of diabetes (years)
<5 20,135 (48.7) 5914 (35.7) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
5–9 12,134 (26.3) 4989 (30.1) 1.16 (1.12–1.21) 1.07 (0.87–1.32) 1.14 (1.03–1.27) 1.14 (1.06–1.22) 1.17 (1.11–1.23)
10–14 5497 (13.3) 3006 (18.1) 1.32 (1.26–1.38) 1.12 (0.88–1.42) 1.26 (1.12–1.41) 1.26 (1.16–1.37) 1.35 (1.27–1.44)
≥15 3602 (8.7) 2669 (16.1) 1.50 (1.43–1.57) 1.30 (1.04–1.62) 1.38 (1.22–1.55) 1.46 (1.34–1.60) 1.53 (1.43–1.64)
BMI (kg/m2)
15–19 477 (1.2) 438 (2.6) 1.51 (1.36–1.66) 1.12 (0.63–2.00) 1.30 (0.98–1.73) 1.53 (1.27–1.84) 1.56 (1.37–1.79)
20–24 6127 (14.8) 3419 (20.6) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
25–29 15,249 (36.9) 5762 (34.8) 0.78 (0.75–0.82) 0.72 (0.57–0.90) 0.82 (0.73–0.92) 0.79 (0.73–0.86) 0.78 (0.73–0.83)
≥30 17,577 (42.5) 5382 (32.5) 0.82 (0.78–0.85) 0.64 (0.51–0.81) 0.80 (0.71–0.90) 0.85 (0.78–0.92) 0.82 (0.77–0.87)
Unknown 1938 (4.7) 1577 (9.5) 1.43 (1.34–1.52) 1.17 (0.88–1.55) 1.32 (1.13–1.54) 1.54 (1.37–1.72) 1.42 (1.30–1.56)
Smoking status
Non–smoker 21,930 (53.0) 8245 (49.7) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Current 6819 (16.5) 3309 (20.0) 1.50 (1.44–1.57) 1.09 (0.84–1.40) 1.33 (1.18–1.50) 1.60 (1.48–1.74) 1.54 (1.46–1.63)
Former 10,815 (26.1) 4196 (25.3) 1.07 (1.03–1.12) 1.04 (0.86–1.25) 1.00 (0.91–1.11) 1.09 (1.02–1.17) 1.08 (1.03–1.14)
Unknown 1804 (4.4) 828 (5.0) 0.95 (0.88–1.02) 1.06 (0.78–1.45) 0.88 (0.73–1.06) 1.00 (0.86–1.15) 0.91 (0.82–1.01)
Number of medications
0–1 11,963 (28.9) 3044 (18.4) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
2–4 15,169 (36.7) 5289 (31.9) 1.21 (1.15–1.26) 0.90 (0.67–1.20) 1.07 (0.94–1.23) 1.19 (1.09–1.30) 1.22 (1.16–1.30)
5–9 12,235 (29.6) 6445 (38.9) 1.45 (1.39–1.52) 1.02 (0.79–1.32) 1.15 (1.01–1.31) 1.39 (1.27–1.51) 1.53 (1.44–1.63)
≥10 2001 (4.8) 1800 (10.9) 2.03 (1.91–2.16) 1.03 (0.76–1.39) 1.67 (1.43–1.96) 2.01 (1.79–2.26) 2.18 (1.99–2.38)
HbA1c (%)
<7.00 14,151 (34.2) 5231 (31.6) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
7.00–7.99 9363 (22.6) 3460 (20.9) 1.01 (0.97–1.05) 1.29 (1.03–1.61) 1.04 (0.92–1.16) 0.98 (0.91–1.06) 1.01 (0.95–1.07)
8.00–8.99 5333 (12.9) 1888 (11.4) 0.97 (0.92–1.02) 1.02 (0.77–1.36) 1.12 (0.97–1.29) 0.96 (0.87–1.07) 0.95 (0.88–1.02)
9.00–9.99 3319 (8.0) 1315 (7.9) 1.14 (1.07–1.21) 1.40 (1.01–1.92) 1.24 (1.05–1.46) 1.18 (1.04–1.32) 1.11 (1.02–1.20)
≥10.00 3363 (8.1) 1435 (8.7) 1.35 (1.27–1.43) 1.23 (0.92–1.65) 1.46 (1.23–1.73) 1.43 (1.27–1.60) 1.31 (1.21–1.42)
Missing 5839 (14.1) 3249 (19.6) 1.24 (1.19–1.30) 1.35 (1.09–1.67) 1.38 (1.23–1.54) 1.19 (1.09–1.30) 1.23 (1.16–1.31)
Comorbiditiesc
Hypertension 23,223 (56.1) 9529 (57.5) 0.87 (0.84–0.90) 0.68 (0.58–0.81) 0.76 (0.70–0.83) 0.85 (0.80–0.90) 0.91 (0.87–0.95)
Hyperlipidemia 1343 (3.2) 2655 (16.0) 2.04 (1.95–2.13) 1.68 (1.42–1.98) 1.76 (1.59–1.93) 2.13 (1.97–2.31) 2.33 (2.16–2.51)
History of MI 3033 (7.3) 2548 (15.4) 1.14 (1.09–1.19) 1.14 (0.94–1.39) 1.14 (1.02–1.27) 1.09 (1.00–1.19) 1.20 (1.12–1.28)
History of IS/TIA 2776 (6.7) 2899 (17.5) 1.51 (1.45–1.57) 1.12 (0.93–1.36) 1.39 (1.26–1.54) 1.46 (1.36–1.57) 1.67 (1.57–1.77)
History of IHDd 6146 (14.9) 4052 (24.4) 1.02 (0.98–1.06) 1.10 (0.93–1.30) 0.92 (0.84–1.02) 1.01 (0.94–1.08) 1.03 (0.97–1.09)
COPD 1075 (2.6) 1576 (9.5) 1.77 (1.68–1.87) 1.55 (1.20–2.01) 1.32 (1.14–1.54) 1.65 (1.49–1.83) 1.95 (1.81–2.10)
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Table 4 HRs of death associated with potential risk factors, overall and stratified by eGFR category (Continued)
Thyroid disease 3418 (8.3) 1514 (9.1) 0.92 (0.87–0.97) 0.97 (0.77–1.21) 0.89 (0.79–1.01) 0.98 (0.90–1.08) 0.90 (0.83–0.98)
DVT 2138 (5.2) 1291 (7.8) 1.12 (1.06–1.19) 0.97 (0.76–1.23) 1.10 (0.96–1.27) 1.04 (0.94–1.15) 1.17 (1.08–1.27)
PAD 1742 (4.2) 1953 (11.8) 1.35 (1.28–1.42) 1.01 (0.82–1.24) 1.19 (1.06–1.33) 1.41 (1.29–1.55) 1.44 (1.34–1.55)
Anemia 2097 (5.1) 1464 (8.8) 1.24 (1.17–1.31) 1.05 (0.86–1.28) 1.26 (1.12–1.41) 1.23 (1.11–1.36) 1.29 (1.18–1.40)
Atrial fibrillation 2483 (6.0) 1011 (6.1) 1.01 (0.95–1.07) 1.04 (0.76–1.41) 0.98 (0.83–1.16) 1.05 (0.93–1.18) 1.00 (0.91–1.09)
Heart failure 2850 (6.9) 1161 (7.0) 1.02 (0.96–1.08) 1.07 (0.79–1.44) 1.03 (0.88–1.20) 1.04 (0.93–1.17) 0.99 (0.91–1.08)
Gout 2370 (5.7) 1229 (7.4) 0.98 (0.92–1.04) 0.95 (0.76–1.19) 0.98 (0.86–1.12) 0.99 (0.88–1.10) 1.00 (0.92–1.10)
Cancer 2948 (7.1) 2347 (14.2) 1.49 (1.42–1.55) 1.50 (1.20–1.88) 1.19 (1.07–1.34) 1.34 (1.23–1.45) 1.67 (1.57–1.78)
aAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level, presence of hypertension hyperlidemia, and
history of MI, IS/TIA, IHD. and eGFR category. bAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level,
presence of hypertension hyperlidemia, and history of MI, IS/TIA and IHD. cRelative to absence of comorbidity. dExcluding MI.
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate;
HbA1c, glycated hemoglobin; HR, hazard ratio; IHD, ischemic heart disease; IS, ischemic stroke; MI, myocardial infarction; PAD, peripheral artery disease; TIA,
transient ischemic attack.
Cea Soriano et al. Cardiovascular Diabetology  (2015) 14:38 Page 8 of 15subgroups according to the HbA1c data recorded closest
to their start date: < 7.00%, 7.00–7.99%, 8.00–8.99%,
9.00–9.99%, 10.00–10.99% and ≥ 11.00%. Individuals
without a recorded level of HbA1c in the year before
their start date were included in the ‘missing’ category.
Statistical analysis
Incidence rates of death, MI and IS/TIA were calcu-
lated overall and by eGFR categories. Kaplan–Meier
survival curves for all-cause mortality, MI and IS/TIA
were calculated overall and according to eGFR cat-
egory. Hazard ratios (HRs) and their 95% confidence
intervals (CIs) were calculated using Cox proportional
hazard models adjusted for sex, age, BMI, smoking sta-
tus, hyperlipidemia, hypertension, history of MI, his-
tory of IS/TIA, history of ischemic heart disease
(excluding MI), eGFR category, duration of diabetes,
HbA1c category, and polypharmacy (in the month be-
fore the start date). A two-sided p value < 0.05 was
considered to be statistically significant. Statistical ana-
lyses were performed using the Stata package version
12.0 (StataCorp LP, College Station, TX, USA).
Results
Baseline characteristics and comorbidities
Table 1 shows the main baseline characteristics of pa-
tients with type 2 diabetes included in this study, ac-
cording to their eGFR category. Almost 70% of
patients had an eGFR ≥ 60 mL/min and about 9% had
an eGFR of 15–44 mL/min (CKD stages 3B and 4).
Overall, the mean age at start date was 65.7 years and
there were more men than women in the study cohort
(55.4% and 44.6%, respectively). However, there were
more women than men in the subgroup of patients
with an eGFR < 60 mL/min (58.7% and 41.3%, respect-
ively). Over 75% of patients were overweight or obese
(BMI ≥ 25 kg/m2) and over 65% were using 2–9 drugs
in the month before their start date. About 70% ofpatients had had diabetes for 1–9 years at their start
date, whereas about 5% had had diabetes for < 1 year.
Among patients with a record of HbA1c level, about
60% (29,476/48,858) had an HbA1c level ≥ 7%.
Among the comorbidities we assessed (Table 2),
hypertension was the most prevalent; over 55% of pa-
tients had hypertension. The proportion was highest
among individuals with an eGFR of 15–29 mL/min
(68.3%). A history of MI or IS/TIA was recorded in
9.6% and 9.8% of patients, respectively. Other frequent
comorbidities included cancer (9.1%), hyperlipidemia
(6.9%), heart failure (6.9%), peripheral artery disease
(6.4%), atrial fibrillation (6.0%) and deep vein throm-
bosis (5.9%). The prevalence of comorbidities tended
to be higher in patients with lower eGFRs; about a
third of those with an eGFR of 15–29 mL/min (CKD
stage 4) had hyperlipidemia.Incidences of death, myocardial infarction and stroke
Incidence rates of death, MI, IS/TIA and combined
outcomes stratified by eGFR category and overall are
shown in Figure 1.Mortality
A total of 16,578 (28.6%) patients died during the study
period. The person-time contribution was 379,833
person-years over a median follow-up time of 6.76 years.
The overall mortality was 43.65 deaths per 1000 person-
years (95% CI: 42.99–44.31). There was a marked in-
crease in all-cause mortality with decreasing values of
eGFR. Patients with an eGFR of 15–29 mL/min (CDK
stage 4) showed the highest mortality (210.01 deaths per
1000 person-years [95% CI: 149.91–226.28]), whereas
those with an eGFR ≥ 60 mL/min showed the lowest
mortality (31.99 deaths per 1000 person-years [95% CI:
31.33–32.66]). Kaplan–Meier curves of cumulative inci-
dence of death are shown in Figure 2A.
Table 5 HRs of MI associated with potential risk factors, overall and stratified by eGFR category
Non–MI MI eGFR category
n = 54,511 n = 3435 Overall 15–29 mL/min 30–44 mL/min 45–59 mL/min ≥60 mL/min
Number (%) Number (%) HRa (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI)
Sex
Men 29,966 (55.0) 2151 (62.6) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Women 25,545 (45.0) 1284 (37.4) 0.71 (0.66–0.77) 1.15 (0.74–1.78) 0.90 (0.73–1.11) 0.78 (0.68–0.90) 0.62 (0.56–0.69)
Age at start date (years)
20–49 5573 (10.2) 150 (4.4) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
50–74 35,880 (65.8) 2192 (63.8) 1.73 (1.46–2.05) 0.39 (0.05–2.96) 1.27 (0.31–5.17) 1.04 (0.57–1.91) 1.75 (1.46–2.10)
≥75 13,058 (24.0) 1093 (31.8) 2.99 (2.49–3.59) 0.44 (0.06–3.35) 1.77 (0.44–7.22) 1.76 (0.96–3.23) 3.26 (2.66–4.00)
Duration of diabetes (years)
<5 24,828 (45.6) 1221 (35.6) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
5–9 16,112 (29.6) 1011 (29.4) 1.14 (1.05–1.24) 0.55 (0.29–1.03) 1.04 (0.81–1.34) 1.20 (1.01–1.42) 1.15 (1.04–1.28)
10–14 7845 (14.4) 658 (19.2) 1.43 (1.30–1.58) 1.41 (0.79–2.52) 0.98 (0.73–1.31) 1.62 (1.34–1.95) 1.44 (1.27–1.63)
≥15 5726 (10.5) 545 (15.9) 1.54 (1.39–1.71) 1.41 (0.81–2.46) 1.44 (1.09–1.89) 1.69 (1.38–2.06) 1.47 (1.28–1.70)
BMI (kg/m2)
15–19 863 (1.6) 52 (1.5) 1.25 (0.94–1.66) – 0.73 (0.27–2.01) 1.12 (0.65–1.94) 1.50 (1.05–2.13)
20–24 8999 (16.5) 547 (15.9) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
25–29 19,633 (36.0) 1378 (40.1) 1.08 (0.98–1.19) 1.12 (0.64–1.98) 1.20 (0.91–1.59) 1.05 (0.87–1.27) 1.06 (0.93–1.21)
≥30 21,713 (39.8) 1246 (36.3) 1.01 (0.91–1.12) 0.67 (0.37–1.22) 0.90 (0.67–1.22) 0.99 (0.81–1.22) 1.05 (0.91–1.20)
Unknown 3303 (6.1) 212 (6.2) 1.22 (1.04–1.44) 0.45 (0.16–1.24) 0.95 (0.60–1.48) 1.38 (1.02–1.87) 1.27 (1.01–1.59)
Smoking status
Non–smoker 28,484 (52.3) 1691 (49.2) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Current 9427 (17.3) 701 (20.4) 1.40 (1.28–1.53) 0.84 (0.42–1.70) 1.23 (0.91–1.66) 1.41 (1.17–1.70) 1.43 (1.27–1.59)
Former 14,116 (25.9) 895 (26.1) 0.99 (0.91–1.08) 0.85 (0.52–1.39) 0.87 (0.68–1.11) 1.03 (0.88–1.21) 1.01 (0.91–1.13)
Unknown 2484 (4.6) 148 (4.3) 0.98 (0.82–1.17) 0.74 (0.26–2.14) 1.22 (0.78–1.91) 1.12 (0.80–1.56) 0.89 (0.70–1.12)
Number of medications
0–1 14,314 (26.3) 693 (20.2) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
2–4 19,322 (35.4) 1136 (33.1) 1.15 (1.05–1.27) 0.66 (0.31–1.40) 1.44 (1.02–2.04) 1.31 (1.08–1.59) 1.08 (0.96–1.21)
5–9 17,413 (31.9) 1267 (36.9) 1.18 (1.07–1.30) 0.96 (0.51–1.82) 1.29 (0.93–1.80) 1.22 (1.01–1.48) 1.12 (0.99–1.27)
≥10 3462 (6.4) 339 (9.9) 1.41 (1.23–1.62) 0.65 (0.30–1.44) 1.54 (1.04–2.29) 1.28 (0.97–1.69) 1.57 (1.31–1.89)
HbA1c (%)
<7.00 18,429 (33.8) 953 (27.7) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
7.00–7.99 12,074 (22.2) 749 (21.8) 1.15 (1.05–1.27) 0.98 (0.54–1.78) 1.17 (0.90–1.52) 0.90 (0.74–1.09) 1.30 (1.14–1.48)
8.00–8.99 6721 (12.3) 500 (14.6) 1.33 (1.19–1.49) 0.83 (0.40–1.70) 1.23 (0.89–1.71) 1.22 (0.99–1.51) 1.45 (1.26–1.68)
9.00–9.99 4310 (7.9) 324 (9.4) 1.40 (1.23–1.59) 1.23 (0.54–2.76) 1.28 (0.88–1.89) 1.24 (0.96–1.60) 1.53 (1.30–1.81)
≥10.00 4468 (8.6) 330 (9.6) 1.53 (1.35–1.74) 0.82 (0.38–1.78) 0.89 (0.55–1.43) 1.38 (1.07–1.80) 1.77 (1.51–2.08)
Missing 8509 (15.6) 579 (16.9) 1.24 (1.11–1.37) 1.32 (0.76–2.30) 0.90 (0.67–1.22) 1.23 (1.01–1.50) 1.34 (1.16–1.54)
Comorbiditiesc
Hypertension 30,684 (56.3) 2068 (60.2) 1.05 (0.98–1.13) 0.73 (0.46–1.14) 0.82 (0.67–1.01) 1.08 (0.94–1.25) 1.09 (1.00–1.20)
Hyperlipidemia 3574 (6.6) 424 (12.3) 1.39 (1.25–1.56) 1.57 (1.02–2.41) 1.53 (1.21–1.94) 1.45 (1.20–1.76) 1.31 (1.09–1.58)
History of MI 4778 (8.8) 803 (23.4) 1.94 (1.77–2.12) 2.25 (1.44–3.52) 1.80 (1.41–2.30) 1.99 (1.68–2.37) 1.93 (1.71–2.19)
History of IS/TIA 5187 (9.5) 488 (14.2) 1.29 (1.17–1.43) 1.17 (0.71–1.92) 1.19 (0.92–1.53) 1.21 (1.01–1.45) 1.42 (1.24–1.63)
History of IHDd 9021 (16.5) 1177 (34.3) 1.66 (1.53–1.80) 1.35 (0.88–2.08) 1.34 (1.07–1.68) 1.57 (1.35–1.83) 1.81 (1.62–2.02)
COPD 2453 (4.5) 198 (5.8) 1.17 (1.01–1.35) 0.83 (0.35–1.96) 1.13 (0.78–1.66) 1.08 (0.81–1.43) 1.24 (1.01–1.52)
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Table 5 HRs of MI associated with potential risk factors, overall and stratified by eGFR category (Continued)
Thyroid disease 4648 (8.5) 284 (8.3) 0.96 (0.85–1.09) 1.37 (0.80–2.36) 0.86 (0.64–1.17) 0.91 (0.73–1.13) 1.01 (0.84–1.21)
DVT 3199 (5.9) 230 (6.7) 1.03 (0.90–1.18) 0.43 (0.19–0.98) 1.03 (0.73–1.46) 0.88 (0.68–1.15) 1.17 (0.97–1.40)
PAD 3253 (6.0) 442 (12.9) 1.53 (1.38–1.70) 1.15 (0.70–1.91) 1.55 (1.20–2.00) 1.40 (1.14–1.71) 1.67 (1.45–1.93)
Anemia 3310 (6.1) 251 (7.3) 1.12 (0.98–1.28) 1.04 (0.63–1.73) 0.93 (0.68–1.27) 1.18 (0.94–1.50) 1.18 (0.97–1.44)
Atrial fibrillation 3273 (6.0) 221 (6.4) 1.08 (0.95–1.24) 0.96 (0.41–2.24) 0.77 (0.49–1.22) 1.07 (0.81–1.41) 1.17 (0.99–1.39)
Heart failure 3759 (6.9) 252 (7.3) 1.06 (0.93–1.21) 0.83 (0.39–1.79) 0.59 (0.37–0.95) 1.02 (0.79–1.32) 1.21 (1.03–1.42)
Gout 3359 (6.2) 240 (7.0) 0.93 (0.81–1.06) 1.25 (0.72–2.20) 0.81 (0.57–1.13) 1.17 (0.92–1.49) 0.83 (0.68–1.01)
Cancer 4986 (9.1) 309 (9.0) 1.00 (0.89–1.13) 1.61 (0.92–2.85) 0.83 (0.60–1.14) 1.07 (0.87–1.32) 0.97 (0.82–1.15)
aAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level, presence of hypertension hyperlidemia, and
history of MI, IS/TIA, IHD and eGFR category. bAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level,
presence of hypertension hyperlidemia, and history of MI, IS/TIA, and IHD. cRelative to absence of comorbidity. dExcluding MI.
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate;
HbA1c, glycated hemoglobin; HR, hazard ratio; IHD, ischemic heart disease; IS, ischemic stroke; MI, myocardial infarction; PAD, peripheral artery disease; TIA,
transient ischemic attack.
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The overall incidence rate of MI was 9.26 cases per 1000
person-years (95% CI: 8.96–9.58) over a median follow-up
time of 6.64 years. As for mortality, the incidence rate of MI
increased with decreasing values of eGFR. The incidence
rates of MI for patients with an eGFR of 15–29 mL/min
(CKD stage 4) and ≥ 60 mL/min were 31.65 (95% CI:
26.02–38.51) and 7.44 (95% CI: 7.12–7.77) cases per
1000 person-years, respectively. Kaplan–Meier curves
of cumulative incidence of MI are shown in Figure 2B.
Incidence of ischemic stroke and transient ischemic attack
The overall incidence rate of IS/TIA was 10.39 cases
per 1000 person-years (95% CI: 10.07–10.73) with a
median follow-up time of 6.56 years and a person-time
contribution of 364,258 person-years. An increased in-
cidence rate of IS/TIA was observed with declining
renal function. The incidence rates of IS/TIA were
32.48 cases per 1000 person-years (95% CI: 26.70–
39.51) in patients with CKD stage 4 (eGFRs of 15–
29 mL/min) and 8.65 cases per 1000 person-years (95%
CI: 8.30–9.00) in patients with an eGFR ≥ 60 mL/min.
Kaplan–Meier curves of cumulative incidence of IS/
TIA are shown in Figure 2C.
Cox regression analyses
Risks of death, MI and IS/TIA increased significantly
with decreasing values of eGFR (Table 3). For patients
with eGFR 15–29 mL/min (CKD stage 4), the adjusted
HRs relative to patients with an eGFR ≥ 60 mL/min
were 2.79 (95% CI: 2.57–3.03) for death, 2.33 (95% CI:
1.89–2.87) for MI and 1.77 (95% CI: 1.43–2.18) for IS/
TIA. Corresponding estimates for patients with eGFRs
of 45–59 mL/min were 1.25 (95% CI: 1.20–1.30), 1.27
(95% CI: 1.17–1.38) and 1.09 (95% CI: 1.01–1.18).
HRs for death, MI and IS/TIA associated with other
potential risk factors are shown in Tables 4, 5 and 6.
Overall, women had a lower risk of death and of MIthan men (HR: 0.80 [95% CI: 0.77–0.82] and HR: 0.71
[95% CI: 0.66–0.77], respectively) and the risk of IS/
TIA was similar for men and women. For each out-
come, a longer duration of diabetes was generally asso-
ciated with a greater risk. Overall, the HRs associated
with diabetes diagnosed more than 15 years before the
start date relative to diabetes diagnosed less than
5 years before the start date were 1.50 (95% CI: 1.43–
1.57) for death, 1.54 (95% CI: 1.39–1.71) for MI and
1.27 (95% CI: 1.15–1.41) for IS/TIA. Age was a strong
predictor of death, MI and IS/TIA. The HRs for pa-
tients aged 75 years or older relative to patients aged
20–49 years were 11.24 (95% CI: 9.97–12.67), 2.99
(95% CI: 2.49–3.59) and 5.33 (95% CI: 4.35–6.54) for
death, MI and IS/TIA, respectively. BMI did not affect
the risk of MI or IS/TIA significantly. The risk of
death, however, was significantly lower for overweight
patients (BMI of 25–29 kg/m2) and obese patients
(BMI ≥ 30 kg/m2) than for individuals with a BMI of
20–24 kg/m2 (HR: 0.78 [95% CI: 0.75–0.82] and HR
0.82 [95% CI: 0.78–0.85], respectively). Conversely,
underweight patients (BMI of 15–19 kg/m2) were at
higher risk of death than individuals with a BMI of 20–
24 kg/m2 (HR: 1.51 [95% CI: 1.36–1.66]).
Patients with a history of MI had a greater risk of MI
(HR: 1.94 [95% CI: 1.77–2.12]) than patients without
such a history. Similarly, a history of IS/TIA was a
strong predictor of recurrent IS/TIA (HR: 3.27 [95% CI:
3.03–3.53]). Hyperlipidemia was associated with an in-
creased risk of death (HR: 2.03 [95% CI: 1.94–2.13]), MI
(HR: 1.39 [95% CI: 1.25–1.56]) and IS/TIA (HR: 1.23
[95% CI: 1.09–1.38]), but hypertension was not. A gen-
eral trend for increased risk of death, MI and IS/TIA as-
sociated with increasing HbA1c levels was observed. For
patients with HbA1c levels ≥ 11%, the adjusted HRs rela-
tive to patients with HbA1c levels < 7% were 1.43 (95%
CI: 1.33–1.55) for death, 1.63 (95% CI: 1.37–1.93) for
MI and 1.66 (95% CI: 1.42–1.94) for IS/TIA.
Table 6 HRs of IS or TIA associated with potential risk factors, overall and stratified by eGFR category
Non–IS/TIA IS/TIA eGFR category
n = 54,161 n = 3785 Overall 15–29 mL/min 30–44 mL/min 45–59 mL/min ≥60 mL/min
Number (%) Number (%) HRa (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI) HRb (95% CI)
Sex
Men 30,055 (55.5) 2062 (54.5) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Women 24,106 (44.5) 1723 (45.5) 0.95 (0.89–1.02) 1.52 (0.94–2.46) 1.07 (0.85–1.33) 0.91 (0.80–1.04) 0.93 (0.86–1.02)
Age at start date (years)
20–49 5614 (10.4) 109 (2.9) 1 (−) – – 1 (−) 1 (−)
50–74 35,722 (66.0) 2350 (62.1) 2.83 (2.32–3.43) 0.82 (0.53–1.25) 0.74 (0.60–0.92) 1.54 (0.80–2.99) 2.76 (2.25–3.39)
≥75 12,825 (23.7) 1326 (35.0) 5.33 (4.35–6.54) 1 (−) 1 (−) 2.69 (1.38–5.24) 5.95 (4.77–7.42)
Duration of diabetes (years)
<5 24,591 (45.4) 1458 (38.5) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
5–9 15,945 (29.4) 1178 (31.1) 1.12 (1.04–1.21) 0.99 (0.58–1.69) 1.10 (0.85–1.42) 1.12 (0.96–1.30) 1.12 (1.01–1.23)
10–14 7874 (14.5) 629 (16.6) 1.16 (1.06–1.28) 0.73 (0.37–1.43) 1.05 (0.78–1.42) 1.14 (0.95–1.37) 1.20 (1.06–1.36)
≥15 5751 (10.6) 520 (13.7) 1.27 (1.15–1.41) 1.26 (0.72–2.22) 1.35 (1.01–1.82) 1.15 (0.94–1.41) 1.29 (1.13–1.48)
BMI (kg/m2)
15–19 851 (1.6) 64 (1.7) 1.18 (0.91–1.52) 1.26 (0.29–5.55) 1.65 (0.82–3.34) 1.44 (0.89–2.33) 0.98 (0.69–1.39)
20–24 8894 (16.4) 652 (17.2) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
25–29 19,554 (36.1) 1457 (38.5) 1.01 (0.92–1.10) 0.71 (0.38–1.32) 1.09 (0.80–1.47) 1.13 (0.93–1.36) 0.97 (0.86–1.09)
≥30 21,625 (39.9) 1334 (35.2) 0.93 (0.84–1.02) 0.70 (0.39–1.27) 1.03 (0.75–1.40) 1.10 (0.91–1.34) 0.86 (0.76–0.98)
Unknown 3237 (6.0) 278 (7.3) 1.24 (1.07–1.43) 1.31 (0.63–2.69) 1.45 (0.96–2.18) 1.40 (1.06–1.85) 1.11 (0.91–1.36)
Smoking status
Non–smoker 28,212 (52.1) 1963 (51.9) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
Current 9463 (17.5) 665 (17.6) 1.19 (1.09–1.30) 0.74 (0.33–1.65) 1.20 (0.88–1.64) 1.13 (0.94–1.37) 1.24 (1.11–1.38)
Former 14,046 (25.9) 965 (25.5) 1.03 (0.95–1.11) 1.09 (0.66–1.81) 0.80 (0.62–1.04) 0.91 (0.78–1.07) 1.12 (1.01–1.24)
Unknown 2440 (4.5) 192 (5.1) 1.06 (0.91–1.24) 1.66 (0.81–3.40) 1.17 (0.75–1.83) 1.14 (0.85–1.54) 0.97 (0.79–1.20)
Number of medications
0–1 14,249 (26.3) 758 (20.0) 1 (−) 1 (−) 1 (−) 1 (−) 1 (−)
2–4 19,205 (35.5) 1253 (33.1) 1.14 (1.04–1.25) 1.48 (0.68–3.23) 1.02 (0.72–1.46) 1.17 (0.97–1.41) 1.12 (1.00–1.25)
5–9 17,266 (31.9) 1414 (37.4) 1.28 (1.16–1.40) 1.06 (0.51–2.20) 1.11 (0.80–1.54) 1.16 (0.97–1.40) 1.34 (1.20–1.51)
≥10 3441 (6.4) 360 (9.5) 1.65 (1.44–1.89) 1.15 (0.50–2.62) 1.42 (0.96–2.09) 1.77 (1.38–2.27) 1.64 (1.36–1.97)
HbA1c (%)
<7.00 18,214 (33.6) 1168 (30.9) 1 (−) 1 (−) 1 (−) 1 (−)
7.00–7.99 12,029 (22.2) 794 (21.0) 1.02 (0.93–1.12) 1.56 (0.89–2.74) 0.95 (0.72–1.25) 0.96 (0.81–1.14) 1.04 (0.92–1.17)
8.00–8.99 6730 (12.4) 491 (13.0) 1.12 (1.00–1.24) 0.72 (0.31–1.63) 1.17 (0.83–1.63) 0.93 (0.75–1.15) 1.22 (1.06–1.39)
9.00–9.99 4297 (7.9) 337 (8.9) 1.30 (1.15–1.47) 1.15 (0.46–2.87) 1.24 (0.84–1.83) 1.32 (1.03–1.68) 1.33 (1.14–1.56)
≥10.00 4474 (8.3) 324 (8.6) 1.33 (1.17–1.51) 1.17 (0.53–2.58) 0.72 (0.42–1.24) 1.13 (0.86–1.48) 1.52 (1.31–1.77)
Missing 8417 (15.5) 671 (17.7) 1.20 (1.09–1.33) 1.36 (0.77–2.41) 0.96 (0.72–1.30) 1.15 (0.96–1.39) 1.28 (1.13–1.44)
Comorbiditiesc
Hypertension 30,384 (56.1) 2368 (62.6) 1.07 (1.00–1.14) 0.81 (0.52–1.28) 1.06 (0.84–1.33) 1.09 (0.95–1.25) 1.07 (0.98–1.16)
Hyperlipidemia 3648 (6.7) 350 (9.2) 1.23 (1.09–1.39) 1.79 (1.15–2.79) 1.42 (1.10–1.82) 1.21 (0.98–1.48) 1.17 (0.96–1.43)
History of MI 5134 (9.5) 447 (11.8) 0.97 (0.87–1.08) 1.12 (0.65–1.91) 0.77 (0.57–1.03) 1.06 (0.87–1.30) 0.98 (0.84–1.14)
History of IS/TIA 4710 (8.7) 965 (25.5) 3.26 (3.02–3.52) 1.97 (1.25–3.12) 2.89 (2.33–3.59) 3.09 (2.68–3.57) 3.57 (3.22–3.95)
History of IHDd 9308 (17.2) 890 (23.5) 1.16 (1.07–1.27) 0.81 (0.50–1.31) 1.45 (1.15–1.83) 1.06 (0.91–1.24) 1.18 (1.05–1.32)
COPD 2458 (4.5) 193 (5.1) 1.04 (0.89–1.20) 1.15 (0.56–2.39) 0.79 (0.50–1.26) 1.07 (0.81–1.41) 1.03 (0.85–1.26)
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Table 6 HRs of IS or TIA associated with potential risk factors, overall and stratified by eGFR category (Continued)
Thyroid disease 4571 (8.4) 361 (9.5) 1.01 (0.90–1.13) 0.72 (0.40–1.31) 0.97 (0.72–1.29) 0.99 (0.81–1.21) 1.07 (0.91–1.25)
DVT 3139 (5.8) 290 (7.7) 1.15 (1.02–1.29) 0.67 (0.32–1.39) 1.50 (1.09–2.07) 1.30 (1.05–1.60) 1.02 (0.85–1.21)
PAD 3330 (6.1) 365 (9.6) 1.22 (1.09–1.36) 0.96 (0.54–1.68) 1.35 (1.02–1.77) 1.36 (1.11–1.67) 1.15 (0.98–1.35)
Anemia 3298 (6.1) 263 (6.9) 1.04 (0.92–1.19) 0.82 (0.47–1.44) 1.01 (0.74–1.38) 1.05 (0.83–1.33) 1.08 (0.90–1.30)
Atrial fibrillation 3273 (6.0) 221 (5.8) 0.95 (0.83–1.09) 0.61 (0.22–1.68) 0.82 (0.52–1.29) 0.85 (0.63–1.13) 1.05 (0.89–1.24)
Heart failure 3755 (6.9) 256 (6.8) 0.97 (0.86–1.11) 0.76 (0.30–1.91) 1.08 (0.74–1.57) 1.06 (0.83–1.34) 0.95 (0.80–1.12)
Gout 3299 (6.1) 300 (7.9) 1.17 (1.04–1.32) 0.86 (0.47–1.59) 1.15 (0.84–1.59) 1.34 (1.07–1.66) 1.11 (0.94–1.32)
Cancer 4845 (8.9) 450 (11.9) 1.30 (1.18–1.44) 0.84 (0.42–1.69) 1.33 (1.01–1.75) 1.09 (0.90–1.33) 1.43 (1.25–1.63)
aAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level, presence of hypertension hyperlidemia, and
history of MI, IS/TIA, IHD and eGFR category. bAdjusted for sex, age at start date, duration of diabetes, BMI, smoking status, number of medications, HbA1c level,
presence of hypertension hyperlidemia, and history of MI, IS/TIA, and IHD. cRelative to absence of comorbidity. dExcluding MI.
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate;
HbA1c, glycated hemoglobin; HR, hazard ratio; IHD, ischemic heart disease; IS, ischemic stroke; MI, myocardial infarction; PAD, peripheral artery disease; TIA TIA,
transient ischemic attack.
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In a large population of patients with type 2 diabetes,
incidence rates of death and cardiovascular events for
each eGFR category were higher than those reported
for patients with CKD in the general population [1],
suggesting that diabetes adds to the burden of CKD.
This may be explained in part by the higher prevalence
of known risk factors for death and cardiovascular
events in patients with diabetes and impaired renal
function, including obesity, hypertension, hyperlipid-
emia and history of cardiovascular events.
In the present study, a reduced eGFR was a strong
and independent risk factor for death and cardiovascu-
lar events. The association between lower eGFRs and
increased all-cause mortality was consistent with ob-
servations from previous studies in various populations
of patients with diabetes [1,20-26]. An association be-
tween renal impairment and increased risk of cardio-
vascular events was also observed in an observational
study from the Swedish National Diabetes Register
[25]. This study, however, excluded patients with CKD
stages 4 and 5 (eGFR < 30 mL/min). Reduced eGFR
was also identified as a risk factor for cardiovascular
events in a small US population of patients with type 2
diabetes [26]. These observations may be explained by
common features in the pathophysiologies of CKD and
type 2 diabetes. Risk factors for cardiovascular events
such as increased levels of procoagulant biomarkers,
anemia and endothelial dysfunction have been shown
to be associated with both reduced kidney function
[40-42] and type 2 diabetes [43-45]. These factors may
act synergistically to increase the risk of cardiovascular
events compared with CKD or type 2 diabetes alone.
The association of renal disease with hypoglycemia in
patients with type 2 diabetes is also linked to an in-
creased risk of cardiovascular events [46].
Our study also showed that age and duration of diabetes
were predictors of all-cause mortality and incidence ofcardiovascular events, irrespective of eGFR. This is in line
with results from others [47] and suggests that, as the
population ages and survival of patients with diabetes in-
creases, further efforts will be required to complement on-
going measures to reduce all-cause mortality and risk of
cardiovascular complications and in patients with type 2
diabetes. Traditional cardiovascular risk factors, including
smoking, hyperlipidemia and a history of cardiovascular
events, were also associated with an increased risk of car-
diovascular events and a higher mortality in patients with
type 2 diabetes. These findings echoed results from other
population-based studies [48,49].
In contrast, overweight and obese people (BMI ≥
25 kg/m2) had a lower mortality than individuals with
a BMI of 20–24 kg/m2. Although counterintuitive and
controversial, this ‘obesity paradox’ has been observed
in several cohort studies, patient registries and clinical
trial populations [50].
Overall, our results support the current UK guidelines
[51], which recommend monitoring renal function annu-
ally in all individuals with type 2 diabetes, regardless of
the presence or absence of nephropathy. The guidelines
also recommend addressing traditional cardiovascular
risk factors such as hyperlipidemia and smoking, which
we found to be associated with higher risks of death, MI
and IS/TIA in this population.
The present study has several strengths. THIN is a
large database representative of the UK population and
has been validated for use in epidemiological studies
[29,30]. It has previously been used to study individ-
uals with diabetes [3,52-54] and patients with CKD
[31]. The suitability of THIN for this study is rein-
forced by the fact that laboratory test results are reli-
ably and routinely recorded in the database; 90% of
patients in our large and diverse cohort had a valid
serum creatinine measurement. Our results from a pri-
mary care database may also be more generalizable
than studies from selected populations such as referred
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Other strengths of our study include a long follow-up
period and careful ascertainment of MI and IS/TIA
cases. This was deemed particularly important for IS/
TIA in order to mitigate the observed tendency of
Read codes to overestimate the number of IS/TIA
cases. In common with all observational studies, however,
ours may suffer from uncontrolled confounding. Although
we tried to minimize this by adjusting results for several
potential risk factors, residual confounding cannot be
ruled out. It should also be noted that the levels of urine
albumin were not systematically reported in THIN during
the study period and it was therefore impossible to adjust
analyses for this potential confounder [55,56].
NICE guidelines on the management of CKD were
updated in January 2015 and now recommend the use
of the CKD-EPI equation for the calculation of eGFR
from serum creatinine concentration [57]. During the
study period (2000–2005), however, the MDRD and
the Cockcroft–Gault equations were routinely used;
the MDRD equation was used in THIN and recom-
mended by NICE and was therefore selected for the
present study. Additionally, the MDRD equation has
been shown to be more accurate than the Cockcroft–
Gault formula in patients with CKD and diabetes [58].
The MDRD equation has also previously been used in
a study of CKD in THIN [31]. It should be noted, how-
ever, that eGFR was calculated from a single serum
creatinine measurement. To estimate the extent of
eGFR misclassification, patients with a valid serum cre-
atinine concentration recorded between 91 and
366 days after their start date were identified (n =
47,022, 81% of the study population). Among those pa-
tients, 14,528 had an eGFR < 60 mL/min on their start
date, and the diagnosis of impaired renal function was
confirmed by subsequent creatinine measurement in
12,055 individuals (83%). Conversely, 90% of patients
(n = 29,240) who had an eGFR ≥ 60 mL/min on their start
date and who had a valid creatinine measurement in the
91–366-day period following their start date remained in
the same eGFR category. The fact that ethnicity is not re-
corded in THIN may also have led to misclassification;
eGFR may have been underestimated in black people.
Conclusions
In conclusion, this retrospective study based on a UK
primary care database confirms the high prevalence of
impaired renal function in patients with type 2 dia-
betes. Our findings show that all-cause mortality and
the risk of cardiovascular events increase significantly
with decreasing values of eGFR. In line with current
UK guidelines for the treatment of type 2 diabetes, our
results suggest that physicians should closely monitor
renal function in patients with type 2 diabetes andinitiate lifestyle changes and/or medication to delay
progression of CKD and prevent end-stage renal dis-
ease. Management of associated cardiovascular risks
such as hyperlipidemia and smoking should also be ad-
equately addressed, given the very high risk of adverse
cardiovascular events in patients with both type 2 dia-
betes and impaired renal function.
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